Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.
R
R
Kanagasabay
M J
MJ
Unsworth-White
G
G
Farnsworth
E J
EJ
Haxby
E E
EE
Smith
D000721:Ancrod / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003327:Coronary Disease / Q000601:surgery*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy; D017211:Treatment Failure
D000721:Ancrod; D000925:Anticoagulants; D007611:Aprotinin; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; D015842:Serine Proteinase Inhibitors; C035838:danaparoid